Dassault Systèmes (DSY) Q2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2025 earnings summary
9 Feb, 2026Executive summary
Q2 and H1 2025 delivered solid results with total revenue up 6% in Q2 and 5% in H1, driven by strong subscription and 3DEXPERIENCE performance, and EPS reaching €0.30 in Q2.
The business showed resilience and momentum in transportation, mobility, space, defense, energy, and AI-driven cloud infrastructure.
Life Sciences was flat overall, but saw a shift from R&D to manufacturing and mid-teens growth outside MEDIDATA; notable customer wins and regulatory compliance advances were achieved.
Infrastructure & Cities segment expanded into data centers, focusing on sustainability and energy efficiency.
AI and regulatory compliance emerged as significant growth drivers, with new solutions and strategic partnerships launched.
Financial highlights
Q2 2025 non-IFRS total revenue was €1.52 billion (+6% y/y); H1 revenue reached €3.10 billion (+5% y/y); software revenue up 6% in Q2 and 5% in H1.
Recurring revenue comprised 83% of software revenue in H1, with subscription revenue up 10% in Q2 and 13% YTD.
Q2 2025 non-IFRS operating margin was 29.3%; H1 margin 30.1%; Q2 non-IFRS EPS was €0.30, H1 non-IFRS EPS €0.61.
Cash and cash equivalents at H1 2025 end were €4.08 billion; net cash position €1.51 billion.
Cash flow from operations for H1 2025 was €1.15 billion, up from €1.13 billion in H1 2024.
Outlook and guidance
Full-year 2025 non-IFRS guidance: total and software revenue growth of 6–8%, EPS growth of 7–10%, and operating margin of 32.2–32.4%.
Q3 2025 non-IFRS revenue guidance: €1.485–1.535 billion, with software up 5–9% and subscriptions 10–15%.
Recurring revenue expected to grow 7–8%, with subscription growth of 13–15%.
Guidance excludes impacts from new acquisitions, restructuring, and certain one-time items.
Mid-term ambition is to double non-IFRS diluted EPS by 2029, leveraging 3D UNIV + RSES and generative AI.
Latest events from Dassault Systèmes
- Q2 revenue and EPS rose, cloud and AI advanced, ArisGlobal boosts Life Sciences growth.DSY
Q2 202625 Jul 2026 - Revenue and EPS rose, margins expanded, and Life Sciences strengthened by ArisGlobal acquisition.DSY
Q2 2026 Investor call23 Jul 2026 - Q3 revenue up 4% to €1.46B; FY EPS guidance reaffirmed, with Q4 growth acceleration expected.DSY
Q3 20249 Jul 2026 - FY25 revenue rose 4% to €6,240M, with ARR at €4.5B and FY26 growth targeted at 3–5%.DSY
Q4 2025 Investor Call9 Jul 2026 - Pascal Daloz takes over as Chairman and CEO as the company advances its Industrial AI strategy.DSY
Investor update8 Jul 2026 - Q1 2026 saw 3% revenue growth, strong cash flow, and confirmed full-year guidance.DSY
Q1 2026 Investor Call23 Apr 2026 - Q1 2026 saw 3% revenue growth, strong cash flow, and confirmed outlook with robust AI and cloud momentum.DSY
Q1 202623 Apr 2026 - FY26 targets 3–5% revenue growth, margin expansion, and strong ARR momentum.DSY
Q4 202511 Feb 2026 - Revenue and EPS rose, with robust cloud and 3DEXPERIENCE growth; outlook remains strong.DSY
Q2 20249 Feb 2026